Perennial Allergic Rhinitis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 57 pages report, published by Global Markets Direct

Keywords : Perennial Allergic Rhinitis Therapeutic Products under Development, Key Players in Perennial Allergic Rhinitis Therapeutics, Perennial Allergic Rhinitis Pipeline Overview, Perennial Allergic Rhinitis Pipeline, Perennial Allergic Rhinitis Pipeline Assessment

Report ThumbnailSeptember-2013
Perennial Allergic Rhinitis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Perennial Allergic Rhinitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis. Perennial Allergic Rhinitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Perennial Allergic Rhinitis.
- A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Perennial Allergic Rhinitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Perennial Allergic Rhinitis, H2 2013 7
  • Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 22
  • Assessment by Combination Products, H2 2013 23
  • Assessment by Route of Administration, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Molecule Type, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 27
  • List of Tables
  • Number of Products Under Development for Perennial Allergic Rhinitis, H2 2013 7
  • Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Shionogi & Co., Ltd., H2 2013 15
  • GlaxoSmithKline plc, H2 2013 16
  • Pfizer Inc., H2 2013 17
  • Teva Pharmaceutical Industries Limited, H2 2013 18
  • GenMont Biotech Inc., H2 2013 19
  • VentiRx Pharmaceuticals, Inc., H2 2013 20
  • Adamis Pharmaceuticals Corporation, H2 2013 21
  • Assessment by Monotherapy Products, H2 2013 22
  • Assessment by Combination Products, H2 2013 23
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Stage and Molecule Type, H2 2013 27
  • Perennial Allergic Rhinitis Therapeutics - Drug Profile Updates 40
  • Perennial Allergic Rhinitis Therapeutics - Discontinued Products 45
  • Perennial Allergic Rhinitis Therapeutics - Dormant Products 46
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Perennial Allergic Rhinitis Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Perennial Allergic Rhinitis 7
  • Perennial Allergic Rhinitis Therapeutics under Development by Companies 9
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Perennial Allergic Rhinitis Therapeutics - Products under Development by Companies 14
  • Companies Involved in Perennial Allergic Rhinitis Therapeutics Development 15
  • Shionogi & Co., Ltd. 15
  • GlaxoSmithKline plc 16
  • Pfizer Inc. 17
  • Teva Pharmaceutical Industries Limited 18
  • GenMont Biotech Inc. 19
  • VentiRx Pharmaceuticals, Inc. 20
  • Adamis Pharmaceuticals Corporation 21
  • Perennial Allergic Rhinitis - Therapeutics Assessment 22
  • Assessment by Monotherapy Products 22
  • Assessment by Combination Products 23
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Drug Profiles 28
  • fluticasone furoate - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • beclomethasone dipropionate - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • VTX-1463 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • S-555739 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • GMNL-32 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • (montelukast sodium + levocetirizine) - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • APC-3000 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • PF-06444753 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • PF-06444752 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Perennial Allergic Rhinitis Therapeutics - Drug Profile Updates 40
  • Perennial Allergic Rhinitis Therapeutics - Discontinued Products 45
  • Perennial Allergic Rhinitis Therapeutics - Dormant Products 46
  • Perennial Allergic Rhinitis - Product Development Milestones 47
  • Featured News & Press Releases 47
  • Feb 22, 2013: Teva Pharma To Present Additional Data On Qnasl At 2013 AAAAI Annual Meeting 47
  • Nov 09, 2012: Teva Pharma's Qnasl Demonstrates Efficacy Profile In Pediatric Patients With Seasonal Allergic Rhinitis In Phase III Study 48
  • Mar 26, 2012: Teva Announces FDA Approval Of QNASL For Treatment Of Allergic Rhinitis 49
  • Mar 05, 2012: Teva Reports Positive Results From Four Phase III Clinical Studies Of QNASL To Treat Allergic Rhinitis 50
  • Dec 06, 2011: Meda Receives US Patent For Astepro 52
  • Nov 05, 2011: Sunovion’s Investigational Ciclesonide Nasal Aerosol In HFA Propellant, Demonstrated Positive Results In Patients With Perennial Allergic Rhinitis 52
  • Oct 31, 2011: Teva To Present New Data On QNASL At 2011 American College of Allergy, Asthma And Immunology Annual Meeting 54
  • May 14, 1998: Rhone-Poulenc Rorer submits New Drug Application for once-daily, Non-Sedating Antihistamine 55
  • Oct 20, 1995: Approval Of Kestine(Ebastine) Received in Denmark; New Antihistamine Now Approved in three European Countries 55
  • Sep 13, 1994: Rhone-Poulenc Rorer And Fisons Sign Agreements To Market Respiratory Products In Europe 55
  • Appendix 56
  • Methodology 56
  • Coverage 56
  • Secondary Research 56
  • Primary Research 56
  • Expert Panel Validation 56
  • Contact Us 57
  • Disclaimer 57

Please select a license type

Share

Related Products

Global Markets DirectPerennial Allergic Rhinitis - Pipeline Review, H2 2013Product ThumbnailPerennial Allergic Rhinitis - Pipeline Review, H2 2013, Industry ReportProduct #: 113310
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved